Companies /Healthcare

Biocryst Pharmaceuticals Inc

NASDAQ: BCRX Drug Manufacturers - Specialty & Generic
$7.22
▼ $0.10 (−1.37%) today
Markets closed · 9:31pm ET

BCRX at a Glance

Valuation
Market cap
$1.9B
Profitability
Revenue (TTM)
$961.5M
Profit margin
-37.4%
EPS (TTM)
$-1.28
Price
52-week range
$6 – $11
Street target
$20.45

Headquartered in Durham, NC Fiscal year ends December NASDAQ: BCRX biocryst.com

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a global biotechnology company that develops and commercializes medicines for hereditary angioedema (HAE) and other rare diseases.

Its main commercial product is ORLADEYO (berotralstat), an oral, once-daily plasma kallikrein inhibitor for preventing HAE attacks. ORLADEYO is available as capsules and as an oral pellet formulation. The pellets launched for children aged 2 to under 12 in August 2026 and were approved by the FDA for patients aged 12 and older in October 2026.

In the U.S., ORLADEYO is distributed through CareMed as the company's sole-source specialty pharmacy partner. The European ORLADEYO business was sold to Neopharmed Gentili in October 2025.

BioCryst also earns revenue from RAPIVAB (peramivir injection), including orders from international partners, and from licensing, including European rights to navenibart.

The pipeline includes:
- **Navenibart:** A long-acting plasma kallikrein inhibitor in the pivotal ALPHA-ORBIT trial for HAE, dosed every three or six months.
- **BCX17725:** A KLK5 inhibitor in Phase 1 development for Netherton syndrome.

After acquiring Astria Therapeutics in January 2026, the company is closing its Birmingham research site to shift toward an external R&D model focused on rare diseases. Updated

Latest Activity

BCRXBioCryst Pharmaceuticals
Q3 2026
EPS
$0.14
est $0.12+21.7%
Revenue
$180M
est $166M+8.8%

BioCryst raised full-year total revenue guidance to $715 million to $730 million even after absorbing Birmingham closure charges in GAAP results. ORLADEYO carried the quarter, though part of the upside came from an initial inventory build at new sole-source pharmacy CareMed.

Quarterly EPS — reported vs estimate

BCRX Coverage

Frequently Asked Questions

What does BioCryst Pharmaceuticals do?

BioCryst Pharmaceuticals is a global biotechnology company that develops and commercializes medicines for hereditary angioedema (HAE) and other rare diseases. Its main commercial product is ORLADEYO (berotralstat), an oral, once-daily plasma kallikrein inhibitor for preventing HAE attacks.

What is the BCRX stock price target?

The Wall Street consensus 12-month price target for BCRX is $20.45.